CLAIMS

1. An Use of an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6) for use inin the manufacture of a medicament for treating multiple myeloma in an individual, wherein the treatment comprises administeringmedicament is to the individual the anti-CD38 antibody,be administered with pomalidomide and dexamethasone,

wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg, the pomalidomide is to be administered at a dose of 4 mg, and the dexamethasone is to be administered at a dose of 40 mg individuals under 75 years of age, or the dexamethasone is to be administered at a dose of 20 mg to individuals 75 years of age or older,

wherein the individual has one or more of: chronic obstructive pulmonary disorder (COPD), asthma, and bronchospasms,

wherein the individual received at least two prior therapies for multiple myeloma,

wherein at least one of the at least two prior therapies for multiple myeloma was lenalidomide and at least one of the two prior therapies was a proteasome inhibitor, and

wherein the treatment extends progression free survival (PFS) and/or overall survival (OS) of the individual.

2. AnUse of an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid

sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6) for use in method ofthe manufacture of a medicament for reversing renal function impairment in an individual with multiple myeloma, wherein the method comprises administeringmedicament is to the individual the anti-CD38 antibody,be administered with pomalidomide and dexamethasone,

wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg, the pomalidomide is to be administered at a dose of 4 mg, and the dexamethasone is to be administered at a dose of 40 mg individuals under 75 years of age, or the dexamethasone is to be administered at a dose of 20 mg to individuals 75 years of age or older,

wherein the individual has received at least two prior therapies for multiple myeloma, and

wherein at least one of the at least two prior therapies for multiple myeloma was lenalidomide and at least one of the at least two prior therapies was a proteasome inhibitor.

3. A liquid pharmaceutical formulation comprising

(a) isatuximab at a concentration of 5-20 mg/ml;

(b) a buffering agent selected from the group consisting of: histidine, acetate, and phosphate;

(c) an excipient selected from the group consisting of: sucrose and mannitol, and

(d) polysorbate 80 (PS80).

4. The liquid pharmaceutical formulation of claim 3, wherein isatuximab is present at a concentration of 5 mg/ml, wherein the buffering agent is histidine and the histidine is at a concentration of 10 mM, wherein the excipient is sucrose and the sucrose is at a concentration of 10% (w/v), wherein the PS80 is present at a concentration of 0.005% (w/v), and wherein the pharmaceutical formulation has a pH of about 6.0 or about 6.5.

5. The liquid pharmaceutical formulation of claim 4, wherein the pH is about 6.5.

6. The liquid pharmaceutical formulation of claim 3, wherein isatuximab is present at a concentration of 20 mg/ml, wherein the buffering agent is histidine and the histidine is at a concentration of 20 mM, wherein the excipient is sucrose and the sucrose is present at a concentration of 10% (w/v), wherein the PS80 is present at a concentration of 0.02% (w/v), and wherein the pharmaceutical formulation has a pH of about 6.0.

7. A method of treating multiple myeloma in an individual, comprising administering to the individual an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6), pomalidomide, and dexamethasone,

wherein the anti-CD38 antibody is administered at a dose of 10 mg/kg, the pomalidomide is administered at a dose of 4 mg, and the dexamethasone is administered at a dose of 40 mg wherein the individual is under 75 years of age, or at a dose of 20 mg wherein the individual 75 years of age or older,

wherein the individual received at least two prior therapies for multiple myeloma,

wherein at least one of the at least two prior therapies for multiple myeloma was lenalidomide and at least one of the two prior therapies was a proteasome inhibitor, and

wherein the treatment extends progression free survival (PFS) and/or the treatment extends over all survival (OS) of the individual.

8. A method of improving renal impairment in an individual in need thereof, wherein the individual has multiple myeloma, comprising administering to the individual an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6), pomalidomide, and dexamethasone,

wherein the anti-CD38 antibody is administered at a dose of 10 mg/kg, the pomalidomide is administered at a dose of 4 mg, and the dexamethasone is administered at a dose of 40 mg wherein the individual is under 75 years of age, or at a dose of 20 mg wherein the individual is 75 years of age or older, thereby improving renal impairment,

wherein the individual has received at least two prior therapies for multiple myeloma, and wherein at least one of the at least two prior therapies for multiple myeloma was lenalidomide and at least one of the at least two prior therapies was a proteasome inhibitor.

9. The antibody for use according to claim 1 or 2 or method according to claim 7 or 8, wherein the at least two prior therapies did not include treatment with an anti-CD38 antibody and/or treatment with pomalidomide.

104. The antibody for use according to claim 1, 2, or 9, or the method according to any one of claim 7-9claims 1-3, wherein the individual did not respond to at least one of the at least two prior therapies, or wherein the individual relapsed after at least one of the at least two prior therapies, or wherein the individual experienced disease progression during or after the treatment with at least one of the two prior therapies.

115. The antibody for use according to claim 2, 9, or 10, or the method according to any one of claims 8-102-4, wherein the individual with multiple myeloma is selected for the administration based on the individual having renal impairment.

126. The antibody for use or the method according to claim 115, wherein the individual has an estimated glomerular filtration rate (eGFR) less than about 60 mL/min/1.73m^2.

137. The antibody for use according to any one of claims claim 2 and 9-12, or the method according to any one of claims 8-122-6, wherein the treatment extends progression free survival (PFS) of the individual.

14. 8. The antibody for use according to any one of claims claim 2 and 9-13, or the method according to any one of claims 8-132-7, wherein the treatment extends overall survival (OS) of the individual.

15. The antibody for use according to any one of claims claim 1, 9-10, and 13, or the method according to any one of claims 7, 9-10, and 13 3-4, and 7, wherein the treatment extends the PFS of the individual by at least about 9 months.

16. The antibody for use according to any one of claims claim 1, 9-10, and 13, or the method according to any one of claims 7, 9-10, and 13 3-4, and 7, wherein the treatment extends the PFS of the individual by at least about 4.5 months relative to an individual having multiple myeloma who received a treatment comprising pomalidomide and dexamethasone without the anti-CD38 antibody.

17. The antibody for use according to any one of claims 1, 9, 10 3-4, and 15-16 or the method according to any one of claims 7, 9, 10, 15 and 16 9-10, wherein the treatment reverses renal function impairment.

18. The antibody for use according to any one of claims 1-2 and 9-17, or the method according to any one of claims 7-17 11, wherein the individual achieves a response to the treatment faster than an individual having multiple myeloma who received a treatment comprising pomalidomide and dexamethasone without the anti-CD38 antibody.

19. The antibody for use according to any one of claims 2 and 9-17, or the method of any one of claims 8-17 -11, wherein the individual achieves a renal response to the treatment faster than an individual having multiple myeloma who received a treatment comprising pomalidomide and dexamethasone without the anti-CD38 antibody.

20. The antibody for use or the method according to claim 19 13, wherein the renal response is a complete renal response.

21. The antibody for use or the method according to claim 19 or 20 14, wherein the complete renal response is sustained for at least 60 days.

~~22~~16. The ~~antibody for~~ use according to any one of claims 1-~~2 and 9-21, or the method according to any one of claims 7-21~~15, wherein the anti-CD38 antibody comprises a heavy chain variable region (V_H) comprising an amino acid sequence of SEQ ID NO: 7 and a light chain variable region (V_L) comprising an amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 9.

~~23~~17. The ~~antibody for~~ use according to any one of claims 1-~~2 and 9-22, or the method according to any one of claims 7-22~~16, wherein the anti-CD38 antibody is isatuximab.

~~24~~18. The ~~antibody for~~ use according to any one of claims 1-~~2 and 9-23, or the method according to any one of claims 7-23~~17, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are to be administered in a first 28-day cycle,

wherein the anti-CD38 antibody is to be administered on Days 1, 8, 15, and 22 of the first 28-day cycle, the pomalidomide is to be administered on each of Days 1-21 of the first 28-day cycle, and the dexamethasone is to be administered on Days 1, 8, 15, and 22 of the first 28-day cycle.

~~25~~19. The ~~antibody for~~ use ~~or the method~~ according to claim ~~24~~18, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are to be further administered in one or more 28-day cycles following the first 28-day cycle,

wherein the anti-CD38 antibody is to be administered on Days 1 and 15 of the one or more 28-day cycles following the first 28-day cycle, the pomalidomide is to be administered on each of Days 1-21 of the one or more 28-day cycles following the first 28-day cycle, and the dexamethasone is to be administered on Days 1, 8, 15, and 22 of the one or more 28-day cycles following the first 28-day cycle.

~~26~~20. The ~~antibody for~~ use ~~or the method~~ according to claim ~~24~~18 or ~~25~~19, wherein the pomalidomide and the dexamethasone are to be administered prior to the anti-CD38 antibody on Day 1 of the first 28-day cycle.

~~27~~21. The ~~antibody for~~ use ~~or the method~~ according to any one of claims ~~24-26~~18-20, wherein the dexamethasone is to be administered prior to the anti-CD38 antibody on Days 8, 15, and 22 of the first 28 -day cycle, and wherein the anti-CD38 antibody is to be administered prior to the pomalidomide on Days 8 and 15 of the first 28-day cycle.

~~28~~22. The ~~antibody for~~ use ~~or the method~~ according to any one of claims ~~24-27~~18-21, wherein the pomalidomide and the dexamethasone are to be administered prior to the anti-CD38 antibody on Day 1 of the one or more 28-day cycles following the first 28-day cycle.

~~29~~23. The ~~antibody for~~ use ~~or the method~~ according to any one of claims ~~24-28~~18-22, wherein the dexamethasone is to be administered prior to the anti-CD38 antibody, and wherein the anti-CD38 antibody is to be administered prior to the pomalidomide on Day 15 of the one or more 28-day cycles following the first 28-day cycle.

~~30~~24. The ~~antibody for~~ use according to any one of claims 1-~~2 and 9-23, or the method according to any one of claims 7-23~~17, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are to be administered in a first 28-day cycle,

wherein the anti-CD38 antibody is to be administered once every week of the first 28-day cycle, the pomalidomide is to be administered for 21 days of the first 28-day cycle, and the dexamethasone is to be administered once every week of the first 28-day cycle.

~~31~~25. The ~~antibody for~~ use ~~or the method~~ according to claim ~~30~~24, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are to be further administered in one or more 28-day cycles following the first 28-day cycle,

wherein the anti-CD38 antibody is to be administered once every other week of the one or more 28-day cycles following the first 28-day cycle, the pomalidomide is to be administered for 21 days of the one or more 28-day cycles following the first 28-day cycle, and the dexamethasone is to be administered once every week of the one or more 28-day cycles following the first 28-day cycle.

32[26]. The antibody for use or the method according to claim 30[24] or 31[25], wherein the pomalidomide and the dexamethasone are to be administered prior to the anti-CD38 antibody in the first 28-day cycle.

33[27]. The antibody for use or the method according to any one of claims 30-32[24-26], wherein the dexamethasone is to be administered prior to the anti-CD38 antibody and wherein the anti-CD38 antibody is to be administered prior to the pomalidomide in the first 28-day cycle.

34[28]. The antibody for use or the method according to any one of claims 30-33[24-27], wherein the pomalidomide and the dexamethasone are to be administered prior to the anti-CD38 antibody in the one or more 28-day cycles following the first 28-day cycle.

35[29]. The antibody for use or the method according to any one of claims 30-34[24-28], wherein the dexamethasone is to be administered prior to the anti-CD38 antibody, and wherein the anti-CD38 antibody is to be administered prior to the pomalidomide in the one or more 28-day cycles following the first 28-day cycle.

36[30]. The antibody for use according to any one of claims 1-2 and 9-35, or the method according to any one of claims 7-29, wherein the anti-CD38 antibody is to be administered intravenously.

37[31]. The antibody for use according to any one of claims 1-2 and 9-36, or the method according to any one of claims 7-30, wherein the pomalidomide is to be administered orally.

38[32]. The antibody for use according to any one of claims 1-2 and 9-37, or the method according to any one of claims 7-37[31], wherein the dexamethasone is to be administered orally.

3933. The antibody for use according to any one of claims 1-2 and 9-37 or the method according to any one of claims 7-3731, wherein the dexamethasone is to be administered intravenously.

4034. The antibody for use according to any one of claims 1-2 and 9-39 or the method according to any one of claims 7-3933, wherein the individual was refractory to the most recent prior therapy for multiple myeloma.

4135. The antibody for use or the method according to claim 4034, wherein the most recent prior therapy was lenalidomide.

4236. The antibody for use or the method according to claim 4034, wherein the most recent prior therapy was a proteasome inhibitor.

4337. The antibody for use according to any one of claims 1-2 and 9-42, or the method according to any one of claims 7-36, wherein the proteasome inhibitor is selected from the group consisting of: bortezomib, carfilzomib, and ixazomib.

4438. The antibody for use according to any one of claims 1-2 and 9-43, or the method according to any one of claims 7-37, wherein the lenalidomide and the proteasome inhibitor were administered in combination.

4539. The antibody for use according to any one of claims 1-2 and 9-44, or the method according to any one of claims 7-38, wherein the individual has chronic obstructive pulmonary disorder (COPD).

4640. The antibody for use according to any one of claims 1-2 and 9-45, or the method according to any one of claims 72-39, wherein the individual has asthma.

4741. The antibody for use according to any one of claims 1-2 and 9-46, or the method according to any one of claims 72-40, wherein the individual has bronchospams.

4842. The antibody for use according to any one of claims 1-2 and 9-47, or the method according to any one of claims 7-41, wherein the individual has one or more cytogenetic abnormalities selected from the group consisting of: del(17p), t(4;14), and t(14;16).

4943. The antibody for use according to any one of claims 1-2 and 9-48, or the method according to any one of claims 7-42, wherein the individual is at least 65 but less than 75 years of age.

5044. The antibody for use according to any one of claims 1-2 and 9-48, or the method according to any one of claims 7-42, wherein the individual is 75 years of age or older.

5145. The antibody for use according to any one of claims 1-2 and 9-50, or the method according to any one of claims 7-1-44, wherein the individual has received at least three prior therapies for multiple myeloma.

5246. The antibody for use according to any one of claims 1-2 and 9-51, or the method according to any one of claims 7-5145, wherein the individual is East Asian.

5347. The antibody for use according to any one of claims 1-2 and 9-52, or the method according to any one of claims 7-5246, wherein the individual is Stage III according to the International Staging System (ISS).

5448. The antibody for use according to any one of claims 1-2 and 9-53, or the method according to any one of claims 7-53 1-47, wherein the individual is Stage III according to the Revised International Staging System (R-ISS).

5549. The antibody for use according to any one of claims 1-2 and 9-54, or the method according to any one of claims 7-5448, wherein the individual is minimal residual disease (MRD) negative at a threshold of 10^{-4} or less after treatment.

~~56~~50. The ~~antibody for~~ use ~~or the method~~ according to claim ~~55~~49, wherein the individual is MRD negative at a threshold of 10^{-5} or less after treatment.

~~57~~51. The ~~antibody for~~ use ~~or the method~~ according to claim ~~56~~50, wherein the individual is MRD negative at a threshold of 10^{-6} or less after treatment.

~~58~~52. The ~~antibody for~~ use ~~or the method~~ according to any of claims ~~55-57~~49-51, wherein MRD is assessed via next generation sequencing (NGS).

~~59~~53. The ~~antibody for~~ use ~~or the method~~ according to any of claims ~~55-58~~49-52, wherein MRD is assessed via next generation flow cytometry (NGF).

~~60~~54. A kit comprising an anti-CD38 antibody for use in combination with pomalidomide and dexamethasone for treating an individual having multiple myeloma according to the ~~antibody for~~ use according to any one of claims 1-~~2 and 9-59 or the method of any one of claims 7-59~~53.